Ariad’s Strategic Review, Step Two
Research - Ariad Pharmaceuticals (ARIA) took the second step in its ongoing strategic restructuring on Monday, announcing the sale of its European unit and rights to Iclusig … Continue Reading
Read NowResearch
Simply Sit on That Sarepta Trade, and More Updates
Research - The NASDAQ Biotech Index Fund (IBB) failed to break out from $285 last week (discussed two weeks ago in our webinar) and subsequently lost key … Continue Reading
Premium: Read Now
Does The Latest For Linzess Read Through to Synergy?
Research - Synergy Pharma (SGYP) fell briefly this morning when Phase V Research reported that Ironwood’s (IRWD) Linzess (linaclotide) is producing significant rates of adverse events in real world use, and that the drug may even be too dangerous to remain on the market.
Premium: Read Now
Our First ‘Healthcare Huddle’ Webinar
Research - At PropThink, we experimented with some educational/informational webinars late in 2015 and early in 2016. The reception from our members was great.
Read Now
Bluebird Bio’s CALD Data, And Other Updates
Research - Bluebird bio (BLUE) released interim data from the ongoing Phase 2/3 Starbeam Study (ALD-102) this morning and will present the results at AAN today, evaluating Lenti-D in cerebral adrenoleukodystrophy (CALD), known colloquially as Lorenzo’s Oil disease.
Premium: Read NowAriad’s Brigatinib May Finally Get Its Day
Research - Every stock has its day. Ariad Pharmaceuticals (ARIA) has had a few. From safety issues with its only marketed product Iclusig in 2014, that sent the stock reeling from $20 to $2, to repeat takeover rumors over the last few years that sent the stock soaring.
Premium: Read Now
Oncology Conferences Approach: AACR in April
Research - With Allergan (AGN) and Pfizer (PFE) calling off plans to merge this week, the biotech sector rallied in a big way. Why? In part, Allergan … Continue Reading
Read Now